AI Article Synopsis
- - The study analyzed the performance of the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale among older adults in Lima, Peru, including those with Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively healthy controls.
- - Involving 276 participants, the scale showed excellent reliability (ICC: .996) and good internal consistency (Cronbach's alpha: .937), but could not distinguish between MCI and control participants while effectively assessing severity in AD patients.
- - The research concluded that the ADCS-ADL is a reliable functional assessment tool for AD in Peru, with suggestions for future studies to adapt it for individuals with lower educational backgrounds.
Article Abstract
Background: The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale is a versatile functional assessment tool for patients with Alzheimer's disease (ad). We evaluated its performance in controls, Peruvians with MCI or AD.
Methods: A cross-sectional study of older adults attending a neurology institute in Lima (Peru) with mild cognitive impairment (MCI), ad or cognitively healthy. Test-retest reliability (intraclass correlation coefficient, ICC; internal consistency, Cronbach's alpha) and validity were assessed.
Results: We enrolled 276 individuals (ad: 113, MCI: 68, controls: 95) with no age, sex, educational level, and depressive symptom differences. Reliability was ideal (ICC: .996), and Cronbach's alpha was adequate (.937). The ADCS-ADL could not differentiate MCI from controls but did differentiate ad severity. The ADCS-ADL correlated highly with nearly all tools.
Conclusions: The ADCS-ADL scale is reliable in a population with ad in Lima, Peru. Future work may validate a tool for Peruvians with lower educational levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581136 | PMC |
| http://dx.doi.org/10.1177/15333175221104354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with soybean lecithin-derived α-GPC (SHCog™) improves scopolamine-induced cognitive declines in mice via regulating cholinergic neurotransmission and enhancing neural plasticity in the hippocampus.
Tissue Cell
December 2024
Department of Food Science and Nutrition, Hallym University, Chuncheon 24252, Republic of Korea. Electronic address:
Mild cognitive impairment is a diagnostic category marked by declines in memory and cognitive function that are less severe than those observed in Alzheimer's disease. Previous studies have indicated that individuals with mild cognitive impairment have an elevated risk of progressing to Alzheimer's disease. The hippocampus is well known to play pivotal roles in memory and cognitive functions.
View Article and Find Full Text PDFSenescent brain cell types in Alzheimer's disease: Pathological mechanisms and therapeutic opportunities.
Neurotherapeutics
January 2025
Department of Neurology, Washington University School of Medicine in St Louis, MO, USA; St Louis VA Medical Center, St Louis, MO, USA. Electronic address:
Cellular senescence is a cell state triggered by programmed physiological processes or cellular stress responses. Stress-induced senescent cells often acquire pathogenic traits, including a toxic secretome and resistance to apoptosis. When pathogenic senescent cells form faster than they are cleared by the immune system, they accumulate in tissues throughout the body and contribute to age-related diseases, including neurodegeneration.
View Article and Find Full Text PDFBlood plasma proteomic markers of Alzheimer's disease, current status and application prospects.
Expert Rev Proteomics
January 2025
Skolkovo Institute of Science and Technology, Moscow, Russian Federation.
Introduction: Identifying early risks of developing Alzheimer's disease (AD) is a major challenge as the number of patients with AD steadily increases and requires innovative solutions. Current molecular diagnostic modalities, such as cerebrospinal fluid (CSF) testing and positron emission tomography (PET) imaging, exhibit limitations in their applicability for large-scale screening. In recent years, there has been a marked shift toward the development of blood plasma-based diagnostic tests, which offer a more accessible and clinically viable alternative for widespread use.
View Article and Find Full Text PDFSearching for new drugs to treat Alzheimer's disease dementia through multiple pathways.
World J Clin Cases
January 2025
Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.
Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!